Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $7.5 million.

  • Spyre Therapeutics' Accounts Payables rose 4437.56% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 4437.56%. This contributed to the annual value of $666000.0 for FY2024, which is 9598.41% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Accounts Payables is $7.5 million, which was up 4437.56% from $3.7 million recorded in Q2 2025.
  • Spyre Therapeutics' Accounts Payables' 5-year high stood at $20.8 million during Q2 2023, with a 5-year trough of $666000.0 in Q4 2024.
  • For the 5-year period, Spyre Therapeutics' Accounts Payables averaged around $6.2 million, with its median value being $3.3 million (2021).
  • In the last 5 years, Spyre Therapeutics' Accounts Payables skyrocketed by 234963.07% in 2023 and then tumbled by 9598.41% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Accounts Payables stood at $3.3 million in 2021, then crashed by 79.6% to $677000.0 in 2022, then soared by 2349.63% to $16.6 million in 2023, then crashed by 95.98% to $666000.0 in 2024, then surged by 1019.67% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $3.7 million for Q2 2025, and $3.7 million during Q1 2025.